Scholarlink

<p>Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer with ≥1 <i>PIK3CA</i>, <i>AKT1</i>, and/or <i>PTEN</i> alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月4日

查看全文
  • Neil M. Iyengar,
  • Joyce A. O’Shaughnessy,
  • Heather N. Moore,
  • Erika Hamilton,
  • Komal L. Jhaveri,
  • Cynthia X. Ma,
  • Karen Tedesco,
  • Monali Vasekar,
  • Sarah Donahue,
  • Hope S. Rugo

摘要

Capivasertib, an AKT inhibitor, approved in combination with fulvestrant for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer with ≥1 PIK3CA, AKT1, and/or PTEN alterations, significantly improved progression-free survival in the CAPItello-291 phase 3 trial. However, capivasertib-associated adverse events of diarrhea, rash, and hyperglycemia may require proactive management. This article provides practical recommendations to support prevention and early intervention to optimize adherence and treatment outcomes.